M&A / Deals

Alzheimer’s biotech Korsana to go public via reverse merger

Pharmaphorum

By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.

M&A / Deals Neuroscience Read full story

pharminent April 2, 2026 (Last updated: April 2, 2026)

Pharmaphorum

By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer’s.

M&A / Deals Neuroscience Read full story

Related Stories

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

CordenPharma inks AmbioPharm buyout to continue peptide production expansion

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

You May Have Missed

Eli Lilly issues data sharing ultimatum to 340B hospitals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

ASCO26: In vivo oncology approaches continue to show promise